Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot3 International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 BaselineMeasureEvidence
.... 15.4 BaselineMeasureReport
.... 15.5 BaselineVariablesList
.... 15.6 BookCitation
.... 15.7 BookPartCitation
.... 15.8 CertaintyOfEvidence
.... 15.9 Classification
.... 15.10 CohortDefinition
.... 15.11 Comment
.... 15.12 ComparativeBaselineMeasureEvidence
.... 15.13 ComparativeEvidence
.... 15.14 ComparativeEvidenceReport
.... 15.15 ComparativeEvidenceReportExpanded
.... 15.16 ComparativeEvidenceReportSubject
.... 15.17 ComparativeEvidenceSynthesisReport
.... 15.18 ComparativeParticipantFlowEvidence
.... 15.19 ComparatorGroup
.... 15.20 ComparatorOnlyEvidence
.... 15.21 Comparison
.... 15.22 CompositeRating
.... 15.23 ConceptualCohortDefinition
.... 15.24 ConceptualComparatorDefinition
.... 15.25 ConceptualExposureDefinition
.... 15.26 DatabaseCitation
.... 15.27 DatabaseEntryCitation
.... 15.28 DatasetCitation
.... 15.29 DateAsRating
.... 15.30 DichotomousIntendedOutcome
.... 15.31 EndpointAnalysisPlan
.... 15.32 EvidenceAssessment
.... 15.33 EvidenceList
.... 15.34 EvidenceReport
.... 15.35 EvidenceReportPackage
.... 15.36 EvidenceReportSubject
.... 15.37 EvidenceSynthesisEvidence
.... 15.38 ExposureGroup
.... 15.39 GroupAssignment
.... 15.40 GroupR6
.... 15.41 Guideline
.... 15.42 InterventionOnlyEvidence
.... 15.43 JournalArticleCitation
.... 15.44 M11ReportContainer
.... 15.45 M11ReportSection01
.... 15.46 M11ReportSection02
.... 15.47 M11ReportSection03
.... 15.48 M11ReportSection04
.... 15.49 M11ReportSection05
.... 15.50 M11ReportSection06
.... 15.51 M11ReportSection07
.... 15.52 M11ReportSection08
.... 15.53 M11ReportSection09
.... 15.54 M11ReportSection10
.... 15.55 M11ReportSection11
.... 15.56 M11ReportSection12
.... 15.57 M11ReportSection13
.... 15.58 M11ReportSection14
.... 15.59 MetaanalysisEligibilityCriteria
.... 15.60 MetaanalysisOutcomeDefinition
.... 15.61 MetaanalysisStudyGroup
.... 15.62 NetEffectContribution
.... 15.63 NetEffectContributionList
.... 15.64 NetEffectContributions
.... 15.65 NetEffectEstimate
.... 15.66 NonComparativeEvidence
.... 15.67 OutcomeDefinition
.... 15.68 OutcomeImportance
.... 15.69 OutcomeList
.... 15.70 OutcomeMeasureReport
.... 15.71 OutcomeVariablesList
.... 15.72 ParticipantFlowEvidence
.... 15.73 ParticipantFlowEvidenceVariable
.... 15.74 ParticipantFlowReasonEvidenceVariable
.... 15.75 ParticipantFlowReport
.... 15.76 ParticipantFlowVariablesList
.... 15.77 PICOSpecification
.... 15.78 PICOTaggedComposition
.... 15.79 PICOTaggedEvidence
.... 15.80 PreprintCitation
.... 15.81 Rating
.... 15.82 Recommendation
.... 15.83 RecommendationAction
.... 15.84 RecommendationEligibilityCriteria
.... 15.85 RecommendationJustification
.... 15.86 RecommendationPlan
.... 15.87 RecommendationRating
.... 15.88 ResearchStudyDataDictionary
.... 15.89 ResearchStudySite
.... 15.90 ResearchStudySupport
.... 15.91 RiskOfBias
.... 15.92 SearchResults
.... 15.93 SearchStrategy
.... 15.94 SingleStudyEvidence
.... 15.95 SoaPlanDefinition
.... 15.96 SoftwareCitation
.... 15.97 StatisticModel
.... 15.98 StudyComponent
.... 15.99 StudyDesign
.... 15.100 StudyEligibilityCriteria
.... 15.101 StudyGroup
.... 15.102 StudyRegistryRecord
.... 15.103 SummaryOfFindings
.... 15.104 SummaryOfNetEffect
.... 15.105 SystematicReview
.... 15.106 SystematicReviewEligibilityCriteria
.... 15.107 SystematicReviewExcludedStudies
.... 15.108 SystematicReviewIncludedStudies
.... 15.109 VariableDefinition
.... 15.110 WebPageCitation
.... 15.111 ArtifactAssessmentCompared
.... 15.112 ArtifactAssessmentDateAsRating
.... 15.113 ArtifactPublicationStatus
.... 15.114 ArtifactRecorder
.... 15.115 CharacteristicTiming
.... 15.116 CiteAs
.... 15.117 EvidenceVariableHandlingDetail
.... 15.118 GuidelineRegistration
.... 15.119 NumberAnalyzed
.... 15.120 RelatesToClassifier
.... 15.121 RelatesToWithQuotation
.... 15.122 RelativeOutcomeImportance
.... 15.123 RelevantForAutomatedMatching
.... 15.124 ResearchStudyExcludedStudy
.... 15.125 ResearchStudyIncludedStudy
.... 15.126 ResearchStudyIsLowInterventionTrial
.... 15.127 ResearchStudyIsRareDisease
.... 15.128 ResearchStudyNumberOfStudiesIdentified
.... 15.129 ResearchStudyNumberOfStudiesIncluded
.... 15.130 ResearchStudySaeReportingMethod
.... 15.131 ResearchStudySearchStrategy
.... 15.132 ResearchStudySponsorConfidentialityStatement
.... 15.133 ResearchStudyStudyAmendment
.... 15.134 ResearchStudySystematicReviewEligibilityCriteria
.... 15.135 StatisticModelExpression
.... 15.136 StatisticModelIncludeIf
.... 15.137 Desirability Codes Value Set
.... 15.138 EBMonFHIR Profile Name Value Set
.... 15.139 Evidence Rating System Classifier Codes Value Set
.... 15.140 PICO Classification Value Set
.... 15.141 Recommendation Justification Classifier Codes Value Set
.... 15.142 Research Study Document Types Value Set
.... 15.143 ResearchStudy Classifier Value Set
.... 15.144 Search Strategy Characteristic Value Set
.... 15.145 Desirability Code System
.... 15.146 EBMonFHIR Profile Name Code System
.... 15.147 Evidence Rating System Classifier Code System
.... 15.148 Research Study Document Types Code System
.... 15.149 Search Strategy Characteristic Code System
.... 15.150 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.151 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.152 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.153 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.154 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.155 179899
.... 15.156 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.157 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.158 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.159 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.160 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.161 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.162 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.163 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.164 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.165 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.166 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.167 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.168 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.169 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.170 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.171 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.172 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.173 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.174 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.175 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.176 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.177 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.178 27979893 6. Glycemic Targets.
.... 15.179 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.180 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.181 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.182 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.183 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.184 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.185 30467172 Finding my inner Wonder Woman.
.... 15.186 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.187 33008778 Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.
.... 15.188 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.189 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.190 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.191 367832
.... 15.192 367833
.... 15.193 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.194 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.195 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.196 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.197 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.198 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.199 Add-on Amlodipine at 6 weeks
.... 15.200 Adults with diabetes mellitus type 2
.... 15.201 Adults with type 2 diabetes and CVD and CKD
.... 15.202 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.203 Adverse event free and hypertension control
.... 15.204 Adverse event free and hypertension control at 12 weeks
.... 15.205 Adverse Events Report for NCT03421379
.... 15.206 Adverse Events Report for NCT03640312
.... 15.207 Age
.... 15.208 Age with comparator
.... 15.209 Age with intervention
.... 15.210 Aircraft Type
.... 15.211 Aircraft Type with comparator
.... 15.212 Aircraft Type with intervention
.... 15.213 Altitude
.... 15.214 Altitude comparing intervention vs. comparator
.... 15.215 Altitude for enrolled group
.... 15.216 Altitude for screened group
.... 15.217 Altitude with comparator
.... 15.218 Altitude with intervention
.... 15.219 Analyzed Group in PARACHUTE Trial
.... 15.220 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.221 Baseline Characteristics Report for NCT03421379
.... 15.222 Baseline Characteristics Report for NCT03640312
.... 15.223 Baseline Characteristics Report for QUARTET Trial
.... 15.224 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.225 Baseline Measures List for PARACHUTE Trial
.... 15.226 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.227 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.228 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.229 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.230 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.231 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.232 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.233 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.234 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.235 Candesartan 8 mg once daily
.... 15.236 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.237 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.238 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.239 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.240 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.241 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.242 Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)
.... 15.243 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.244 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.245 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.246 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.247 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.248 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.249 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.250 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.251 Citation for EBMonFHIR Implementation Guide
.... 15.252 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.253 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.254 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.255 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.256 Comparative Evidence Report Expanded for QUARTET USA Trial
.... 15.257 Comparative Evidence Report for QUARTET USA Trial
.... 15.258 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.259 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.260 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.261 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.262 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.263 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.264 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.265 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.266 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.267 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.268 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.269 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.270 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.271 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.272 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.273 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.274 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.275 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.276 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.277 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.278 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.279 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.280 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.281 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.282 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.283 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.284 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.285 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.286 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.287 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.288 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.289 ComparatorDefinition: Standard care
.... 15.290 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.291 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.292 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.293 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.294 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.295 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.296 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.297 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.298 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.299 Computable_Publishing_LLC
.... 15.300 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.301 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.302 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.303 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.304 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.305 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.306 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.307 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.308 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.309 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.310 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.311 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.312 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.313 ConceptualCohortDefinition: Nonfatal stroke
.... 15.314 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.315 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.316 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.317 ConceptualCohortDefinition: Severe obesity
.... 15.318 ConceptualCohortDefinition: T1DM or T2DM
.... 15.319 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.320 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.321 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.322 ConceptualCohortDefinition_Cardiovascular_event
.... 15.323 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.324 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.325 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.326 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.327 COVID_19PneumoniaHospitalizedAdult
.... 15.328 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.329 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.330 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.331 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.332 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.333 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.334 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.335 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.336 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.337 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.338 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.339 CTIS2025-523977-40-00 Eligibility Criteria - ARMYDA Study on Coronary Plaque Change with Semaglutide in Diabetes with ACS
.... 15.340 DatabaseCitation: Citation for FEvIR Platform
.... 15.341 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.342 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.343 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.344 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.345 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.346 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.347 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.348 declined randomization in PARACHUTE Study
.... 15.349 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.350 Delany-Moretlwe 2022 clinical trial
.... 15.351 Diabetes treatment medication
.... 15.352 Diastolic blood pressure at 12 weeks
.... 15.353 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.354 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.355 DichotomousIntendedOutcome: New onset depression
.... 15.356 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.357 DichotomousIntendedOutcome: Remission of diabetes
.... 15.358 DichotomousIntendedOutcome: Treatment with opioids
.... 15.359 DIO: Mortality
.... 15.360 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.361 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.362 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.363 Eligibility criteria for NMA_Diabetes
.... 15.364 Eligibility Criteria for QUARTET USA Trial
.... 15.365 Enrolled Group for QUARTET USA Trial
.... 15.366 Enrolled Group PARACHUTE Trial
.... 15.367 Ethnic Group
.... 15.368 Ethnic Group with comparator
.... 15.369 Ethnic Group with intervention
.... 15.370 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.371 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.372 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.373 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.374 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.375 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.376 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.377 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.378 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.379 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.380 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.381 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.382 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.383 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.384 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.385 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.386 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.387 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.388 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.389 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.390 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.391 EvidenceReportSectionCode Value Set
.... 15.392 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.393 EvidenceVariable Handling Extension Value Set
.... 15.394 EvidenceVariable: case_id
.... 15.395 EvidenceVariable: Patient id
.... 15.396 EvidenceVariable: Time of measurement
.... 15.397 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.398 Excluded from PARACHUTE Study
.... 15.399 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.400 ExposureVariable: Age (as continuous variable)
.... 15.401 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.402 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 15.403 ExposureVariable: pht013093.v1.p1 RACE
.... 15.404 ExposureVariable: pht013093.v1.p1 SEX
.... 15.405 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 15.406 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 15.407 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 15.408 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 15.409 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 15.410 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 15.411 ExposureVariable: pht013094.v1.p1 Source_Type
.... 15.412 Family History of Parachute Use
.... 15.413 Family History of Parachute Use with comparator
.... 15.414 Family History of Parachute Use with intervention
.... 15.415 Frequent Flier
.... 15.416 Frequent Flier with comparator
.... 15.417 Frequent Flier with intervention
.... 15.418 GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.419 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.420 GLP-1 Receptor Agonist Group in Adults with type 2 diabetes
.... 15.421 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.422 Glucagon Nasal Powder (Experimental)
.... 15.423 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.424 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.425 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.426 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.427 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.428 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.429 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.430 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.431 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.432 GroupAssignment: Quadpill vs. Candesartan
.... 15.433 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.434 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.435 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.436 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.437 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.438 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.439 Health Survey Score Total
.... 15.440 Health Survey Score Total comparing intervention vs. comparator
.... 15.441 Health Survey Score Total with comparator
.... 15.442 Health Survey Score Total with intervention
.... 15.443 Health Survey Score-Mental Health Subscore
.... 15.444 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.445 Health Survey Score-Mental Health Subscore with comparator
.... 15.446 Health Survey Score-Mental Health Subscore with intervention
.... 15.447 Health Survey Score-Physical Health Subscore
.... 15.448 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.449 Health Survey Score-Physical Health Subscore with comparator
.... 15.450 Health Survey Score-Physical Health Subscore with intervention
.... 15.451 Health-related Quality of Life (Mental) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.452 Health-related Quality of Life (NCT03640312)
.... 15.453 Health-related Quality of Life (Physical) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.454 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.455 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.456 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.457 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.458 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.459 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.460 Height
.... 15.461 Height with comparator
.... 15.462 Height with intervention
.... 15.463 High Blood Pressure Medication Value Set
.... 15.464 History of Acrophobia
.... 15.465 History of Acrophobia with comparator
.... 15.466 History of Acrophobia with intervention
.... 15.467 History of Broken Bones
.... 15.468 History of Broken Bones with comparator
.... 15.469 History of Broken Bones with intervention
.... 15.470 History of Parachute Use
.... 15.471 History of Parachute Use with comparator
.... 15.472 History of Parachute Use with intervention
.... 15.473 Hypertension Control at 12 weeks
.... 15.474 ICD-10-GM Terminale Codes
.... 15.475 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.476 Injury Severity Score 30 days after Impact with comparator
.... 15.477 Injury Severity Score 30 days after Impact with intervention
.... 15.478 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.479 Injury Severity Score on Impact with comparator
.... 15.480 Injury Severity Score on Impact with intervention
.... 15.481 International vs Domestic Flight
.... 15.482 International vs Domestic Flight with comparator
.... 15.483 International vs Domestic Flight with intervention
.... 15.484 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.485 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.486 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.487 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.488 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.489 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.490 Investigator
.... 15.491 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.492 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.493 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.494 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.495 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.496 Jumping from aircraft with empty backpack
.... 15.497 Jumping from aircraft with parachute
.... 15.498 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.499 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.500 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.501 M11 Report for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.502 M11 Report for M11ResearchStudy Template
.... 15.503 M11 Report Section 1 (Protocol Summary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.504 M11 Report Section 1 (Protocol Summary) for M11ResearchStudy Template
.... 15.505 M11 Report Section 10 (Statistical Considerations) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.506 M11 Report Section 10 (Statistical Considerations) for M11ResearchStudy Template
.... 15.507 M11 Report Section 11 (Trial Oversight) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.508 M11 Report Section 11 (Trial Oversight) for M11ResearchStudy Template
.... 15.509 M11 Report Section 12 (Supporting Details) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.510 M11 Report Section 12 (Supporting Details) for M11ResearchStudy Template
.... 15.511 M11 Report Section 13 (Glossary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.512 M11 Report Section 13 (Glossary) for M11ResearchStudy Template
.... 15.513 M11 Report Section 14 (References) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.514 M11 Report Section 14 (References) for M11ResearchStudy Template
.... 15.515 M11 Report Section 2 (Introduction) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.516 M11 Report Section 2 (Introduction) for M11ResearchStudy Template
.... 15.517 M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.518 M11 Report Section 3 (Trial Objectives and Associated Estimands) for M11ResearchStudy Template
.... 15.519 M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.520 M11 Report Section 4 (Trial Design) for M11ResearchStudy Template
.... 15.521 M11 Report Section 5 (Trial Population) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.522 M11 Report Section 5 (Trial Population) for M11ResearchStudy Template
.... 15.523 M11 Report Section 6 (Trial Intervention) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.524 M11 Report Section 6 (Trial Intervention) for M11ResearchStudy Template
.... 15.525 M11 Report Section 7 (Participant Discontinuation) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.526 M11 Report Section 7 (Participant Discontinuation) for M11ResearchStudy Template
.... 15.527 M11 Report Section 8 (Trial Assessments) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.528 M11 Report Section 8 (Trial Assessments) for M11ResearchStudy Template
.... 15.529 M11 Report Section 9 (Adverse Events) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.530 M11 Report Section 9 (Adverse Events) for M11ResearchStudy Template
.... 15.531 M11ResearchStudy Template
.... 15.532 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.533 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.534 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.535 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.536 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.537 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.538 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.539 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.540 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.541 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.542 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.543 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.544 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.545 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.546 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.547 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.548 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.549 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.550 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.551 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.552 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.553 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.554 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.555 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.556 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.557 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.558 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.559 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.560 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.561 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.562 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.563 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.564 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.565 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.566 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.567 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.568 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.569 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.570 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.571 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.572 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.573 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.574 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.575 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.576 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.577 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.578 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.579 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.580 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.581 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.582 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.583 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.584 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.585 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.586 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.587 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.588 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.589 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.590 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.591 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.592 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.593 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.594 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.595 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.596 MAGICapp-derived Group: GLP-1 RA Group in Adults with type 2 diabetes
.... 15.597 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.598 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.599 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.600 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.601 Mean Change in Serum Creatinine (NCT03640312)
.... 15.602 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.603 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.604 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.605 Mean Change in Serum Potassium (NCT03640312)
.... 15.606 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.607 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.608 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.609 Mean Change in Serum Sodium (NCT03640312)
.... 15.610 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.611 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.612 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.613 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.614 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.615 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.616 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.617 Mean Systolic Blood Pressure (NCT03640312)
.... 15.618 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.619 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.620 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.621 Median Age of Parachute Intervention Group
.... 15.622 Medication Adherence (NCT03640312)
.... 15.623 Medication Adherence at 12 weeks
.... 15.624 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.625 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.626 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.627 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.628 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.629 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.630 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.631 Mortality at 14 days
.... 15.632 NCT03421379 Eligibility Criteria
.... 15.633 NCT03640312 Eligibility Criteria
.... 15.634 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.635 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.636 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.637 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.638 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.639 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.640 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.641 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.642 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.643 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.644 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.645 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.646 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.647 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.648 NHANES SEQN Respondent Sequence Number
.... 15.649 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.650 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.651 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.652 NT-proBNP Study Data Dictionary
.... 15.653 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.654 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.655 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.656 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.657 Organ support-free days
.... 15.658 Outcome Importance Rating 100 of All-cause mortality
.... 15.659 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.660 Outcome Importance Rating 5 of New onset depression
.... 15.661 Outcome Importance Rating 5 of Remission of diabetes
.... 15.662 Outcome Importance Rating 5 of Treatment with opioids
.... 15.663 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.664 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.665 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.666 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.667 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.668 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.669 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.670 Outcome Measure List for QUARTET USA Trial
.... 15.671 Outcome Measure Report for QUARTET USA Trial
.... 15.672 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.673 Outcome Measures Report for NCT03421379
.... 15.674 Outcome Measures Report for NCT03640312
.... 15.675 Outcome Variables List for PARACHUTE Trial
.... 15.676 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.677 Outcome: Death or Major Traumatic Injury on Impact
.... 15.678 Outcome: Injury Severity Score 30 days after Impact
.... 15.679 Outcome: Injury Severity Score on Impact
.... 15.680 OutcomeDefinition for All-cause mortality
.... 15.681 OutcomeDefinition for Body weight
.... 15.682 OutcomeDefinition for Cardiovascular mortality
.... 15.683 OutcomeDefinition for Diabetic ketoacidosis
.... 15.684 OutcomeDefinition for End-stage kidney disease
.... 15.685 OutcomeDefinition for Genital infection
.... 15.686 OutcomeDefinition for Health-related quality of life
.... 15.687 OutcomeDefinition for Heart failure
.... 15.688 OutcomeDefinition for Nonfatal myocardial infarction
.... 15.689 OutcomeDefinition for Nonfatal stroke
.... 15.690 OutcomeDefinition for Serious hyperglycaemia
.... 15.691 OutcomeDefinition for Severe gastrointestinal events
.... 15.692 OutcomeDefinition: Injury Severity Score on Impact
.... 15.693 OutcomeDefinition: All-cause mortality
.... 15.694 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.695 OutcomeDefinition: Body weight
.... 15.696 OutcomeDefinition: Cardiovascular mortality
.... 15.697 OutcomeDefinition: Diabetes in remission
.... 15.698 OutcomeDefinition: End-stage kidney disease
.... 15.699 OutcomeDefinition: HbA1c at 12 months
.... 15.700 OutcomeDefinition: HbA1c at 24 months
.... 15.701 OutcomeDefinition: HbA1c at 36 months
.... 15.702 OutcomeDefinition: HbA1c at 6 months
.... 15.703 OutcomeDefinition: HbA1c at 60 months
.... 15.704 OutcomeDefinition: Health-related quality of life
.... 15.705 OutcomeDefinition: Heart failure
.... 15.706 OutcomeDefinition: Mortality at 14 days
.... 15.707 OutcomeDefinition: New onset depression
.... 15.708 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.709 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.710 OutcomeDefinition: Nonfatal stroke
.... 15.711 OutcomeDefinition: Serious hyperglycaemia
.... 15.712 OutcomeDefinition: Severe gastrointestinal events
.... 15.713 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.714 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.715 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.716 OutcomeVariable: HbA1c at 12 months
.... 15.717 OutcomeVariable: HbA1c at 24 months
.... 15.718 OutcomeVariable: HbA1c at 36 months
.... 15.719 OutcomeVariable: HbA1c at 6 months
.... 15.720 OutcomeVariable: HbA1c at 60 months
.... 15.721 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.722 OutcomeVariable: New onset depression
.... 15.723 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.724 OutcomeVariable: Remission of diabetes
.... 15.725 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.726 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.727 OutcomeVariable_All_cause_mortality
.... 15.728 OutcomeVariable_Treatment_with_opioids
.... 15.729 PARACHUTE Trial baseline characteristics
.... 15.730 PARACHUTE Trial non participants
.... 15.731 PARACHUTE trial participant flow report
.... 15.732 PARACHUTE Trial Participants
.... 15.733 PARACHUTE Trial Participants assigned an empty backpack
.... 15.734 PARACHUTE trial participants assigned parachute
.... 15.735 PARACHUTE Trial Participants available for randomization
.... 15.736 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.737 PARACHUTE Trial Participants randomized into groups
.... 15.738 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.739 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.740 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.741 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.742 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.743 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.744 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.745 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.746 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.747 PARACHUTE Trial Participants that declined randomization
.... 15.748 PARACHUTE Trial Participants with no contact at 30 days
.... 15.749 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.750 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.751 PARACHUTE Trial Results
.... 15.752 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.753 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.754 Participant Flow Report for NCT03421379
.... 15.755 Participant Flow Report for NCT03640312
.... 15.756 Participant Flow Report for QUARTET USA Trial
.... 15.757 Participant Flow Variables List for PARACHUTE Trial
.... 15.758 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.759 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.760 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.761 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.762 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.763 ParticipantFlowMeasure: Exclusion from analysis
.... 15.764 ParticipantFlowMeasure: Inclusion in analysis
.... 15.765 Participants Excluded from PARACHUTE Study
.... 15.766 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.767 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.768 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.769 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.770 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.771 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.772 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.773 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.774 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.775 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.776 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.777 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.778 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.779 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.780 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.781 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.782 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.783 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.784 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.785 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.786 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.787 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.788 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.789 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.790 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.791 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.792 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.793 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.794 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.795 Placebo
.... 15.796 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.797 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.798 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.799 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.800 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.801 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.802 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.803 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.804 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.805 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.806 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.807 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.808 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.809 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.810 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.811 Quadpill once daily
.... 15.812 QUARTET USA Trial Control Group
.... 15.813 QUARTET USA Trial Quadpill group
.... 15.814 randomized into groups for PARACHUTE Trial
.... 15.815 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.816 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.817 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.818 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.819 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.820 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.821 Reasons for exclusion from QUARTET USA Trial
.... 15.822 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.823 Recommendation Justification Code System
.... 15.824 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.825 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.826 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.827 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.828 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.829 Remdesivir
.... 15.830 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.831 ResearchStudy Classifier Code System
.... 15.832 Results Section for NCT03421379
.... 15.833 Results Section for NCT03640312
.... 15.834 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.835 Risk of Bias Assessment of PARACHUTE trial
.... 15.836 Risk Of Bias Type Value Set
.... 15.837 Screened Group PARACHUTE Trial
.... 15.838 Search Strategy for NMA_Diabetes
.... 15.839 SearchResults: PubMed search for Wonder Woman
.... 15.840 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.841 SearchStrategy: PubMed search for Wonder Woman
.... 15.842 Sex
.... 15.843 Sex with comparator
.... 15.844 Sex with intervention
.... 15.845 SGLT2 inhibitors Group in Adults with diabetes mellitus type 2
.... 15.846 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.847 SMR-excluded Tlayjeh H J Infect Public Health 33008778
.... 15.848 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.849 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.850 Spanish or English Value Set
.... 15.851 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.852 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.853 StudyEligibilityCriteria for M11Report Example
.... 15.854 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.855 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.856 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.857 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.858 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.859 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.860 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.861 Summary of Findings - QUARTET USA Trial
.... 15.862 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.863 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.864 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.865 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.866 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.867 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.868 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.869 Systolic blood pressure at 12 weeks
.... 15.870 Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
.... 15.871 Time to integration of results in a recommendation
.... 15.872 VariableDefinition: Comparator
.... 15.873 VariableDefinition: Condition(s)
.... 15.874 VariableDefinition: Date of birth
.... 15.875 VariableDefinition: Date of measurement
.... 15.876 VariableDefinition: Gender
.... 15.877 VariableDefinition: NTproBNP
.... 15.878 VariableDefinition: Unit
.... 15.879 Velocity
.... 15.880 Velocity comparing intervention vs. comparator
.... 15.881 Velocity for enrolled group
.... 15.882 Velocity for non participant group
.... 15.883 Velocity with comparator
.... 15.884 Velocity with intervention
.... 15.885 WebPageCitation: A HEvKA Update Summary
.... 15.886 Weight
.... 15.887 Weight with comparator
.... 15.888 Weight with intervention